RHYTHM PHARMACEUTICALS, INC. Investment Income, Net
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Investment Income, Net of $3.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. investment income, net for the quarter ending 2026-06-30 was $3.22M, a 0.68% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. investment income, net for the quarter ending 2026-03-31 was $3.55M, a 2.34% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. investment income, net for the quarter ending 2025-12-31 was $4.08M, a 16.22% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. investment income, net for the quarter ending 2025-09-30 was $4.33M, a 6.76% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. investment income, net for fiscal 2025 was $15.29M, a 3.96% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. investment income, net for fiscal 2024 was $14.71M, a 5.49% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. investment income, net for fiscal 2023 was $13.95M, a 246.12% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. investment income, net for fiscal 2022 was $4.03M, a 801.34% increase from fiscal 2021.
| Period end | Investment Income, Net 3 month | Investment Income, Net 3 month as first filed | Investment Income, Net 6 month | Investment Income, Net 6 month as first filed | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3.22M 10-Q · filed 2026-08-04 | $6.77M 10-Q · filed 2026-08-04 | $10.86M derived: sum of 3 quarters · filed 2026-08-04 | $15.19M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $3.55M 10-Q · filed 2026-05-05 | $7.64M derived: sum of 2 quarters · filed 2026-05-05 | $11.97M derived: sum of 3 quarters · filed 2026-05-05 | $15.21M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.41M derived: sum of 2 quarters · filed 2026-02-26 | $11.65M derived: sum of 3 quarters · filed 2026-08-04 | $15.29M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $4.33M 10-Q · filed 2025-11-04 | $7.57M derived: sum of 2 quarters · filed 2026-08-04 | $11.21M 10-Q · filed 2025-11-04 | $14.72M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $3.24M 10-Q · filed 2026-08-04 | $6.88M 10-Q · filed 2026-08-04 | $10.40M derived: sum of 3 quarters · filed 2026-08-04 | $14.45M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $3.64M 10-Q · filed 2026-05-05 | $7.15M derived: sum of 2 quarters · filed 2026-05-05 | $11.21M derived: sum of 3 quarters · filed 2026-05-05 | $15.30M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.57M derived: sum of 2 quarters · filed 2026-02-26 | $11.67M derived: sum of 3 quarters · filed 2026-02-26 | $14.71M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $4.05M 10-Q · filed 2025-11-04 | $8.15M derived: sum of 2 quarters · filed 2025-11-04 | $11.20M 10-Q · filed 2025-11-04 | $15.02M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $4.10M 10-Q · filed 2025-08-05 | $7.14M 10-Q · filed 2025-08-05 | $10.96M derived: sum of 3 quarters · filed 2026-02-26 | $14.43M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $3.05M 10-Q · filed 2025-05-07 | $6.87M derived: sum of 2 quarters · filed 2026-02-26 | $10.33M derived: sum of 3 quarters · filed 2026-02-26 | $13.55M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.29M derived: sum of 2 quarters · filed 2026-02-26 | $10.51M derived: sum of 3 quarters · filed 2026-02-26 | $13.95M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $3.47M 10-Q · filed 2024-11-06 | $6.69M derived: sum of 2 quarters · filed 2024-11-06 | $10.13M 10-Q · filed 2024-11-06 | $13.17M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $3.22M 10-Q · filed 2024-08-06 | $6.66M 10-Q · filed 2024-08-06 | $9.70M derived: sum of 3 quarters · filed 2025-02-28 | $10.62M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | $3.44M 10-Q · filed 2024-05-07 | $6.48M derived: sum of 2 quarters · filed 2025-02-28 | $7.40M derived: sum of 3 quarters · filed 2025-02-28 | $7.67M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2022-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $3.96M derived: sum of 2 quarters · filed 2025-02-28 | $4.24M derived: sum of 3 quarters · filed 2025-02-28 | $4.03M 10-K · filed 2025-02-28 | ||
| 2022-09-30 | $920.00K 10-Q · filed 2023-11-08 | $1.19M derived: sum of 2 quarters · filed 2023-11-08 | $988.00K 10-Q · filed 2023-11-08 | $1.49M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $274.00K 10-Q · filed 2023-08-01 | $95.00K 10-Q · filed 2022-08-03 | $434.00K 10-Q · filed 2023-08-01 | $22.00K 10-Q · filed 2022-08-03 | $568.00K derived: sum of 3 quarters · filed 2024-02-29 | $706.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $160.00K 10-Q · filed 2023-05-02 | -$73.00K 10-Q · filed 2022-05-03 | $294.00K derived: sum of 2 quarters · filed 2024-02-29 | $432.00K derived: sum of 3 quarters · filed 2024-02-29 | $453.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $272.00K derived: sum of 2 quarters · filed 2024-02-29 | $293.00K derived: sum of 3 quarters · filed 2024-02-29 | $447.00K 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $138.00K 10-Q · filed 2022-11-08 | $159.00K derived: sum of 2 quarters · filed 2022-11-08 | $313.00K 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $21.00K 10-Q · filed 2022-08-03 | $175.00K 10-Q · filed 2022-08-03 | ||||
| 2021-03-31 | $154.00K 10-Q · filed 2022-05-03 | |||||
| 2020-12-31 | $2.58M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |